SONROTOCLAX | N220711 | BEONE MEDICINES USA INC
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 11420968 | Apr 29, 2039 | — | Yes | Yes | — | — |
BEQALZI (sonrotoclax) received FDA approval under NDA 220711 for indication 002.
New: New record
BEQALZI (sonrotoclax) received FDA approval under NDA 220711 for indication 004.
New: New record
BEQALZI (sonrotoclax) received FDA approval under NDA 220711 for indication 003.
New: New record
BEQALZI (sonrotoclax) received FDA approval under New Drug Application 220711 on an unspecified date.
New: New record
BEONE Medicines USA added U.S. Patent No. 11,420,968 to the Orange Book listing for Beqalzi (sonrotoclax), NDA 220711.
New: New record
BEONE Medicines USA added U.S. Patent 11,420,968 to the Orange Book for BEQALZI (sonrotoclax), NDA 220711.
New: New record
BEONE Medicines USA added patent 11,420,968 to the Orange Book for Beqalzi (sonrotoclax), NDA 220711, product 004.
New: New record
Sonrotoclax (Beqalzi, NDA 220711) added U.S. Patent 11,420,968 to Orange Book listings, effective for generic competition starting Jan 2040.
New: New record